Dysbiosis-associated bile acids slam the brakes on immune checkpoint therapy

Tauro-conjugated bile acids driven by antibiotic-induced gut dysbiosis have been identified as mechanistic drivers of non-response to immune checkpoint inhibitor (ICI) therapy in cancer patients. The study by Mallard de La Varende et al. further establishes γ-glutamyl transferase (γGT) as a predictive biomarker for ICI resistance. These findings provide a molecular explanation for the well-documented clinical observation that antibiotics compromise ICI efficacy.